Skip to Content
Merck
All Photos(2)

Key Documents

GF83525193

Ruthenium

Ruthenium, bar, 25mm x 2mm x 2mm, 99.9%

Synonym(s):

Ruthenium, RU008010

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
Ru
CAS Number:
Molecular Weight:
101.07
MDL number:
UNSPSC Code:
12141739
PubChem Substance ID:
NACRES:
NA.23

Assay

99.9%

form

foil

manufacturer/tradename

Goodfellow 835-251-93

resistivity

7.1 μΩ-cm, 0°C

L × W × thickness

25 mm × 2 mm × 2 mm

bp

3900 °C (lit.)

mp

2310 °C (lit.)

density

12.45 g/cm3 (lit.)

SMILES string

[Ru]

InChI

1S/Ru

InChI key

KJTLSVCANCCWHF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Storage Class Code

13 - Non Combustible Solids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E Tfouni et al.
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Aviva Levina et al.
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
Martin R Gill et al.
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
A Bergamo et al.
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
Lutz Ackermann et al.
Topics in current chemistry, 292, 211-229 (2010-01-01)
Stoichiometric cycloruthenation reactions of substrates containing Lewis-basic functionalities set the stage for efficient ruthenium-catalyzed C-H bond functionalization reactions. Thereby, selective addition reactions of C-H bonds across alkenes or alkynes enabled atom-economical synthesis of substituted arenes. More recently, ruthenium-catalyzed direct arylation

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service